SOURCE: Novo Nordisk A/S

April 27, 2009 08:26 ET

Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - April 27, 2009) - Novo Nordisk A/S - Share repurchase programme

On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 20 April 2009, the following transactions have been made under the programme:

Number of shares Average purchase Transaction price value, DKK Accumulated, last announcement 4,405,141 1,222,317,085 20 April 2009 50,000 259.19 12,959,500 21 April 2009 77,500 260.82 20,213,550 22 April 2009 90,000 264.81 23,832,900 23 April 2009 90,000 267.30 24,057,000 24 April 2009 105,000 272.36 28,597,800 Accumulated under the programme 4,817,641 1,331,977,835

With the transactions stated above, Novo Nordisk owns a total of 29,670,023 treasury shares, corresponding to 4.7% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

The Annual General Meeting of Novo Nordisk A/S, which was held on 18 March 2009, approved a 2.2% reduction in the total share capital by cancellation of 14,000,000 treasury B shares of DKK 1 at a nominal value of DKK 14,000,000. After the legal implementation of the share capital reduction, which is expected to take place after expiry of the legal notice period in June 2009, Novo Nordisk's share capital will amount to DKK 620,000,000 divided into an A share capital of DKK 107,487,200 and a B share capital of DKK 512,512,800. Taking into account the expected cancellation Novo Nordisk would currently own 2.5% of such reduced share capital. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

Company Announcement no 24 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • Further information:


    Outside North America:
    Elin K Hansen
    Tel: (+45) 4442 3450
    Email Contact

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316
    Email Contact


    Outside North America:
    Mads Veggerby Lausten
    Tel: (+45) 4443 7919
    Email Contact

    Kasper Roseeuw Poulsen
    Tel: 4442 4471
    Email Contact

    In North America:
    Hans Rommer
    Tel: (+1) 609 919 7937
    Email Contact